Pancreatic Cancer Research

ResearcherNingbo UniversityActive in the last 2 years

Wei Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1049-7239; OpenAlex author ID A5049542745. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
76
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: none · 2024: 4 papers · 2025: 2 papers

Papers 21

  1. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2025.101152↗
  2. Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002458↗
  3. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/ajcp/aqae038↗
  4. Keratin 17 modulates the immune topography of pancreatic cancer. Co-author DOI 10.1186/s12967-024-05252-1↗
  5. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm13072103↗
  6. Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.5858/arpa.2023-0005-oa↗
  7. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer. Co-author DOI 10.1002/jso.26860↗
  8. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00018-22↗
  9. Development and validation of a nomogram to predict liver metastasis for pancreatic ductal adenocarcinoma after radical resection. First author DOI 10.3389/fonc.2022.1040411↗
  10. Isolated Ovarian Metastasis from Pancreatic Cancer Mimicking Primary Ovarian Neoplasia: Role of Molecular Analysis in Determining Diagnosis. Co-author DOI 10.1089/pancan.2021.0001↗
  11. Splenic-vasculature involvement is associated with poor prognosis in resected distal pancreatic cancer. Co-author DOI 10.1093/gastro/goaa084↗
  12. Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. Co-author DOI 10.4292/wjgpt.v11.i2.25↗
  13. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Co-author DOI 10.1158/1541-7786.mcr-19-0589↗
  14. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Co-author DOI 10.1080/15384047.2016.1210743↗
  15. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… First author DOI 10.1097/sla.0000000000002088↗
  16. Stage III should be subclassified into Stage IIIA and IIIB in the American Joint Committee on Cancer (8th Edition) staging system for pancreatic cancer. Co-author DOI 10.3748/wjg.v24.i22.2400↗
  17. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24723↗
  18. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer ce… Co-author DOI 10.1038/onc.2015.325↗
  19. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. First author DOI 10.1002/cncr.27715↗
  20. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarc… First author DOI 10.1369/0022155412468137↗
  21. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma. Co-author PMID 22670179↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles J. Yeo · 12 shared papers, 2016–2025 · strength 1.61
  2. Avinoam Nevler · 6 shared papers, 2022–2025 · strength 1.16
  3. Aditi Jain · 5 shared papers, 2019–2025 · strength 0.91
  4. Harish Lavu · 5 shared papers, 2017–2025 · strength 0.86
  5. Jonathan Robert Brody · 6 shared papers, 2016–2025 · strength 0.61
  6. Faria Nusrat · 2 shared papers, 2024–2025 · strength 0.47
  7. Christopher William Schultz · 4 shared papers, 2019–2022 · strength 0.39
  8. Lynn McCormick Matrisian · 3 shared papers, 2018–2024 · strength 0.39
  9. Michael Jon Pishvaian · 3 shared papers, 2018–2025 · strength 0.37
  10. Emanuel F. Petricoin · 3 shared papers, 2016–2024 · strength 0.37
  11. Matthew McCoy · 2 shared papers, 2022–2025 · strength 0.35
  12. Rosalie C. Sears · 2 shared papers, 2022–2025 · strength 0.35
  13. Andrew Eugene Hendifar · 2 shared papers, 2024 · strength 0.33
  14. Lucia Roa‐Peña · 2 shared papers, 2024 · strength 0.33
  15. Brent K. Larson · 2 shared papers, 2024 · strength 0.33
  16. Lyanne Delgado Coka · 2 shared papers, 2024 · strength 0.33
  17. Luisa F. Escobar‐Hoyos · 2 shared papers, 2024 · strength 0.33
  18. Kenneth Reed Shroyer · 2 shared papers, 2024 · strength 0.33
  19. Hao Xie · 5 shared papers, 2012–2021 · strength 0.32
  20. Teena Dhir · 3 shared papers, 2019–2021 · strength 0.27
  21. Jordan Michael Winter · 4 shared papers, 2016–2018 · strength 0.23
  22. Sohum D. Patel · 1 shared paper, 2025 · strength 0.23
  23. Xiuli Liu · 3 shared papers, 2013–2021 · strength 0.23
  24. Samantha Z. Brown · 2 shared papers, 2019–2022 · strength 0.21
  25. Jingshu Tong · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.